A new technique known as the Checkerboard Tissue Microarray (TMA) Meth... Needle biopsies blood and urine analysis are the current options a...The Checkerboard TMA Method looks for multiple markers of various ge...The technique will be pivotal in developing a test for prostate canc...Prostate cancer is now the most common cancer to affect men in the U...
A new technique known as the Checkerboard Tissue Microarray (TMA) Method will markedly help in predicting the behaviour of prostate cancer.
Needle biopsies, blood and urine analysis are the current options available to determine how aggressive the cancer // is and whether it is likely to progress. The results of these tests are however not very accurate, resulting in thousands of men undergoing unnecessary surgery for prostate cancer.
The Checkerboard TMA Method looks for multiple markers of various genes associated with prostate cancer including the E2F3 gene. Over expression of the E2F3 gene is a marker of how aggressive the prostate cancer will be.
The technique will be pivotal in developing a test for prostate cancer aggressiveness which may ultimately prevent thousands of men undergoing unnecessary surgery, with its often associated severe side effects including incontinence and impotence.
Prostate cancer is now the most common cancer to affect men in the UK. More than 30,000 men in the UK are diagnosed with the disease and almost 10,000 men die from the disease each year.
The development of this gene-targeted approach towards prostate cancer has been made possible due to our improved understanding of the molecular mechanisms behind the disease. We still have a long way to go before such techniques can be used to improve the lives of millions of people afflicted with the disease.
For routine pathological examination, the needle biopsy samples are embedded in paraffin blocks to facilitate thin sectioning and examination. The new method requires the biopsies to be cut into cubes, which are oriented in an appropriate way to expose a cross-section of the sample.
These reoriented samples are then re-embedded in hot paraffin wax followed by slicing and staining. Samples processed this way retain the antigenicity, which makes it ideal to be tested for tumour progression.
(Date:11/30/2009)... CLEVELAND, Ohio, November 30 Si...oper of medical simulation systems, in collaborati...ROcedure Rehearsal Studio(TM),workshop for the fir...,Germany. , The Simbionix PROcedure Rehea...ator to enable clinicians to create practice scena...
(Date:11/30/2009)...le-aged men and women who engage in high levels of...ge to their knees and increasing their risk for os... at the annual meeting of the Radiological Society...at people with higher physical activity levels may...ies and, thus, at higher risk for developing osteo...
(Date:11/30/2009)...rge proportion of patients who undergo abdominal/p... and unnecessary additional image acquisition resu...ording to a study presented today at the annual me... (RSNA). , "It is the responsibility of all phys...that the dosage is as low as reasonably achievable...
(Date:11/30/2009).... 30, 2009 UT Southwestern Medical Center researc...lies stave off complications associated with asthm...ber issue of Pediatrics, suggest that interventi...ldren who have received specialized topical traini...s, emergency room visits and missed adult workdays...
(Date:11/29/2009)... Moravia,s Nanjing-based Service Deliver...ce , Brno, Czech Republic...tion solution provider, is pleased to announce its... 2009, to be held in Nanjing, China, on November 3...Union-based companies that have established and gr...
... Sixteen QHR hospital clients received unexpe...ry. The payments - ranging from $65,000 to more t...articipating in a unique and innovative partnershi...ps that experience less than projected risk manage...
...family has a correlate relationship with the invas...sted that, unlike E-cadherin, N-cadherin may promo...plore clinical pathological significance of E-cadh...sion of E-cadherin and N-cadherin in 62 cases of n...
...edes are under treatment with the blood-thinning d... Waran, which makes the initiation of treatment a ...ting. Now researchers at Uppsala University have ...of Medicine . , Some 20 research teams in four r...
.... 19 The PepsiCo Foundation today announced a thr...help ensure the survival and well-being of childre...ther are home to 40 percent of the world,s malnour...dren will work towards decreasing newborn and chil...
... Cardium Therapeutics (NYSE Alternext US: CXM) rep...bmitted on January 23, 2009 has been accepted by t...ock Exchange). , , (Logo: http://www.newscom....hange indicating that the company was considered t...
...stry Veteran Will Lead Company in Development of ,...l Food Ingredients , , ORLANDO, Fla., Feb. 19 Va...ck as President & Chief Executive Officer of t...(India) Ltd, Chennai, India) announced last Novemb...
(Date:11/25/2009)..., , RANCHO CORDOVA, Calif., Nov. 25 /PRNew...iary of American Pacific Corporation (Nasdaq: APF...ntal Responsibility and Sustainability Award at th... by the California Manufacturers and Technology As...ociation (IEA) and the Chemical Industry Council o...
(Date:11/25/2009)..., , HARBIN, China, Nov. 25 /PRNew...c. ("China Sky One Medical" or "the Company") (Nas...tical company developing and producing,over-the-co...C"), today,announced that the Company recently pas... of Pharmaceutical and Biological Products ("ICPBP...
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ -...earch report is available in its catalogue: ,, ...ive ,, http://www.reportlinker.com/p0164330/...e.html ,, Rising incidence of breast cancer in... principal factor influencing growth in the mammog...
...2007 American Society of Clinical Oncology (ASCO) ...tients with AML and in,Refractory , ALL Patients P...teraction of Aloxi(R),with , the 5-HT3 Receptor Re...oblastoma Patients,Treated , with Multimodal Thera...Analysis of Irofulven in Second-Line HRPC,Patients...
... -- The Barbara,Ann Karmanos Cancer Institute,s Ph... medicine and oncology, presented the outcome,of o...ncer clinical,trials in North America and chaired ...c cancer therapies at the American Society of,Clin.... , The clinical trial, A Phase III Randomized Ope...